Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.

Bruno Brochet Alessandra SolariJeannette Lechner-ScottFredrik PiehlDawn LangdonRaymond HuppertsKrzysztof SelmajFrancesco PattiLuis BrievaEva Maria MaidaNektaria AlexandriAndrzej SmykAxel NoltingBirgit KellerXavier MontalbanEva Kubala Havrdova

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)

CladT treatment significantly improved the mean MSQoL-54 physical and mental health composite scores over 2 years. CladT efficacy in HRQoL, relapse rates and Expanded Disability Status Scale scores demonstrates its multidimensional effects in MS treatment.

Keyphrases

multiple sclerosis
mental health
mass spectrometry
white matter
physical activity
ms ms
mental illness
combination therapy